Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers
Abstract Precision oncology led to the establishment and widespread application of molecular tumor boards (MTBs)—multidisciplinary units combining molecular and clinical assessment of individual cancer cases for swift selection of personalized treatments. Whole-exome or gene panel sequencing, combin...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2025-06-01
|
| Series: | Molecular Systems Biology |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s44320-025-00125-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849388844608126976 |
|---|---|
| author | Tatiana V Denisenko Anna E Ivanova Alexey Koval Denis N Silachev Lee Jia Gennadiy T Sukhikh Vladimir L Katanaev |
| author_facet | Tatiana V Denisenko Anna E Ivanova Alexey Koval Denis N Silachev Lee Jia Gennadiy T Sukhikh Vladimir L Katanaev |
| author_sort | Tatiana V Denisenko |
| collection | DOAJ |
| description | Abstract Precision oncology led to the establishment and widespread application of molecular tumor boards (MTBs)—multidisciplinary units combining molecular and clinical assessment of individual cancer cases for swift selection of personalized treatments. Whole-exome or gene panel sequencing, combined with transcriptomic, immunohistochemical, and other molecular analyses, often permits dissection of molecular drivers of a tumor and identification of its potential targetable vulnerabilities, instructing clinical oncologists on sometimes unconventional treatment options. However, cancer drivers are often unleashed mutation-independently, especially in breast and gynecological cancers, and deleterious mutations are not always pathogenic. To complement the MTB arsenal, we chart here the molecular toolset we call Signalomics that permits fast and robust assessment of a panel of oncogenic signaling pathways in fresh tumor samples. Using transcriptional reporters introduced in primary tumor cells, this approach identifies the pathways overactivated in a given tumor and validates their sensitivity to targeted therapies, providing actionable insights for personalized treatment strategies. Integration of Signalomics into MTB workflows bridges the gap between molecular profiling and functional pathway analysis, refining clinical treatment decisions and advancing precision oncology. |
| format | Article |
| id | doaj-art-13daa0ea9a484988bf654201962528e8 |
| institution | Kabale University |
| issn | 1744-4292 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | Molecular Systems Biology |
| spelling | doaj-art-13daa0ea9a484988bf654201962528e82025-08-20T03:42:09ZengSpringer NatureMolecular Systems Biology1744-42922025-06-0121895295910.1038/s44320-025-00125-1Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancersTatiana V Denisenko0Anna E Ivanova1Alexey Koval2Denis N Silachev3Lee Jia4Gennadiy T Sukhikh5Vladimir L Katanaev6Kulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyKulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyTranslational Research Centre in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of GenevaKulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyCollege of Materials and Chemical Engineering, Minjiang UniversityKulakov National Medical Research Center of Obstetrics, Gynecology and PerinatologyTranslational Research Centre in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of GenevaAbstract Precision oncology led to the establishment and widespread application of molecular tumor boards (MTBs)—multidisciplinary units combining molecular and clinical assessment of individual cancer cases for swift selection of personalized treatments. Whole-exome or gene panel sequencing, combined with transcriptomic, immunohistochemical, and other molecular analyses, often permits dissection of molecular drivers of a tumor and identification of its potential targetable vulnerabilities, instructing clinical oncologists on sometimes unconventional treatment options. However, cancer drivers are often unleashed mutation-independently, especially in breast and gynecological cancers, and deleterious mutations are not always pathogenic. To complement the MTB arsenal, we chart here the molecular toolset we call Signalomics that permits fast and robust assessment of a panel of oncogenic signaling pathways in fresh tumor samples. Using transcriptional reporters introduced in primary tumor cells, this approach identifies the pathways overactivated in a given tumor and validates their sensitivity to targeted therapies, providing actionable insights for personalized treatment strategies. Integration of Signalomics into MTB workflows bridges the gap between molecular profiling and functional pathway analysis, refining clinical treatment decisions and advancing precision oncology.https://doi.org/10.1038/s44320-025-00125-1Molecular Tumor BoardOncogenic Signaling PathwaysSignalomicsPrecision OncologyBreast and Gynecological Cancers |
| spellingShingle | Tatiana V Denisenko Anna E Ivanova Alexey Koval Denis N Silachev Lee Jia Gennadiy T Sukhikh Vladimir L Katanaev Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers Molecular Systems Biology Molecular Tumor Board Oncogenic Signaling Pathways Signalomics Precision Oncology Breast and Gynecological Cancers |
| title | Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| title_full | Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| title_fullStr | Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| title_full_unstemmed | Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| title_short | Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| title_sort | signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers |
| topic | Molecular Tumor Board Oncogenic Signaling Pathways Signalomics Precision Oncology Breast and Gynecological Cancers |
| url | https://doi.org/10.1038/s44320-025-00125-1 |
| work_keys_str_mv | AT tatianavdenisenko signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT annaeivanova signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT alexeykoval signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT denisnsilachev signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT leejia signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT gennadiytsukhikh signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers AT vladimirlkatanaev signalomicsformoleculartumorboardsandprecisiononcologyofbreastandgynecologicalcancers |